102 results about "Receptor type" patented technology

The invention relates to a donor-recipient typed conjugated polymer containing two thiofuran and pyrrole and the preparation method and applications thereof. Using a construction mode of donor-recipient typed co polymerization for preparing the conjugated polymer can absorb action spectrum, cover UV-Visible and near infrared region to fully use sunlight. The donor uses a constitution unit of two thiofuran and pyrrole with a good plane performance, high density of electron cloud and easy preparation. The preparation of the conjugated polymer is easy, with absorbing spectrum in the UV-Visible and near infrared region of 300 to1000nm and the energy transforming efficiency being 3 percent. The performances of prepared solar batteries are respectively: white light (light intensity of 100mW/cm<2> ) irradiating, the open-circuit voltage is equal to 0.37 to 0.54 V; the short circuit current is equal to 6.69 to 13.8mA/cm<2>; the packing factor is equal to 0.35 to 0.44; and the efficiency of energy transformation is equal to 1 to 3 percent.

A variety of methods for assaying libraries of test compounds as ligands and/or substrates of transport proteins, including both carrier-type and receptor-type transport proteins, are provided. Both in vitro and in vivo screening methods are disclosed. Also provided are methods for screening DNA libraries to identify members that encode transport proteins. Pharmaceutical compositions including compounds identified via the screening methods are also provided.

The present invention provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth. Compounds of the invention include “spectrum selective” kinase modulators, compounds that inhibit, regulate and/or modulate signal transduction across subfamilies of receptor-type tyrosine kinases, including ephrin and EGFR.

The present invention provides new compounds and methods for treating a disease responsive to inhibition of kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity of growth factor receptors, for example a disease responsive to inhibition of receptor type tyrosine kinase signaling, or for example, a disease responsive to inhibition of VEGF receptor signaling.

A conjugate protein comprising an IL-2 and a soluble TGF-beta type II receptor type B and its use in cancer immunotherapy are described.

The object of the present invention is to provide a method for efficiently producing vinegar that contains a higher concentration of acetic acid, wherein a gene involved in the acetic acid fermentation ability is obtained, the acetic acid fermentation ability of an acetic acid bacterium is improved by reducing or deleting the function of the protein encoded by the gene. An acetic acid bacterium with a remarkably improved acetic acid fermentation ability was obtained by obtaining genes encoding an acyl homoserine lactone synthase and an acyl homoserine lactone receptor-type transcription factor that are involved in the quorum-sensing system in the acetic acid bacterium, and modifying the genes so as to reduce or delete the function of the quorum-sensing system. Further provided is a method for more efficiently producing vinegar containing a higher concentration of acetic acid by using the acetic acid bacterium.

The present disclosure is based on the identification of biomarkers of combined genetic variants and imaging measurements, in predicting faster decline in cognitive measures and brain glucose metabolism in populations with Alzheimer's disease or those susceptible to developing Alzheimer's disease. The present disclosure provides a method of treating a patient with Alzheimer's disease (AD) or a subject susceptible to developing AD, comprising: (a) assaying a sample obtained from an early-stage AD patient or a subject susceptible to developing AD for the presence of a brain-derived neurotrophic factor (BDNF) gene mutation and/or a protein tyrosine phosphatase receptor-type, Z polypeptide 1 (Ptprz1) gene mutation; (b) determining whether the patient or subject is positive for brain amyloid-beta (Aβ), wherein the presence of brain Aβ in combination with the BDNF gene and/or Ptprz1 gene mutation correlates with a prediction of rapid cognitive decline; and (c) treating the patient or subject with early and aggressive therapy appropriate to treat AD with rapid cognitive decline.

Method for identifying myeloid or plasmacytoid dendritic cells provided by a mammal, stimulated or unstimulated, comprising the steps of: a) preparing a cell sample; b) contracting the cell sample myeloid or plasmacytoid dendritic cells to form a complex; c) detecting the complex; characterized in that the phosphatase is the Receptor type Tyrosine Phosphatase Gamma Protein (PTPRG), acting as a specific marker of said dendritic cells, and in that the compound is a polypeptide capable of selectively bind to the PTPRG or to a fragment thereof or to a oligonucleotide complementary to a PTPRG mRNA logonucleotide in such a manner as to allow the selective recognizing of the dendritic cells in the cell sample.

The invention discloses a small molecular polypeptide TAT-siP-PTPN1-HA and application thereof in preparation of a medicament for treating or preventing senile dementia. An artificially synthesized TAT protein transduction structural domain and an siP-PTPN1-HA fusion protein polypeptide TAT-siP-PTPN1-HA are used, TAT can carry the siP-PTPN1-HA protein polypeptide to pass through a blood-brain carrier via blood to be absorbed by neurons, and by applying the small molecular polypeptide TAT-siP-PTPN1-HA to an in-vivo senile dementia model, the biological action of blocking the binding of miR-124 and protein tyrosine phosphatase, non-receptor type 1, PTPN1 3'-non-coding sequence (3'-untranslated region, 3'-UTR) can be effectively realized, the expression of PTPN1 is further effectively reversed, excessive phosphorylation of microtube-associated protein tau and amyloid protein deposition, as well as animal learning and memory disorders represented by an senile dementia model animal are improved, and a new direction is provided for further development of the medicaments for clinical treatment of senile dementia.

This invention relates to methods and compositions for overcoming the dose-dependent down regulation of interleukin 10 (IL-10) by expressing, in addition to an interleukin 10 (IL-10) peptide, an IL-10 receptor type 1 (IL-10R1) peptide. The methods have use in treating a variety of diseases and symptoms, including but not limited to neuropathic or chronic pain; symptoms and physiological damage associated with multiple sclerosis, spinal cord injury, ALS, neuroinflammation, arthritis and other diseases of the joint; and autoimmune diseases.

The present invention discloses a safe and environmentally friendly cichorium intybus chloroplast transformation system establishment method, which comprises: (1) establishing a high frequency regeneration system of a cichorium intybus leaf explant; (2) constructing a safe and environmentally friendly cichorium intybus chloroplast site-specific integration expression vector; and (3) adopting a gene gun bombardment method to transform the cichorium intybus explant, and carrying out three rounds of resistance screening to obtain the chloroplast transgene strain. According to the present invention, the novel safe selection marker gene PMI is adopted to replace the traditional antibiotic marker gene aadA to construct the chloroplast site-specific integration expression vector and establish the cichorium intybus chloroplast transformation system, wherein the system has advantages of high screening efficiency, high exogenous gene expression level, strong transgenic plant bio-safety and the like; and receptor types of chloroplast transformation are broadened, and technical platforms are built for genetic improvement on cichorium intybus, or application of cichorium intybus chloroplast as a bioreactor to produce animal oral vaccines, medical proteins and the like.

The invention provides a prophylactic agent or therapeutic agent for fibrodysplasia ossificans progressiva, containing as an active ingredient a binding inhibitor that inhibits interaction between activin and activin A receptor type I (ACVR1), or an expression suppressor that suppresses expression of activin.

The invention belongs to the field of macromolecular photoelectronic materials, and discloses a main chain donor-side chain receptor type conjugated polymer and a preparation method thereof as well asapplication to a single-component organic solar battery. The structure of the conjugated polymer is as follows: as shown in the specification, wherein n is a positive integer less than or equal to 1,000,000, a is a positive integer from 3 to 40, R is methyl, methoxyl, nitrile group or a fluorine atom, R1, R2, R3 and R4 are the same or different alkyl chains, and A is an electron-deficient conjugated unit structure which is at least one of diazosulfide and a derivative thereof, benzotriazolimide and a derivative thereof, naphthalene dithiadiazole and a derivative thereof, and naphthylene ditrizole and a derivative thereof. A main chain of the conjugated polymer disclosed by the invention is of a P-type conjugated structure, and narrow band gap light absorption type n-type small molecules are introduced into a side chain; the main chain donor-side chain receptor type conjugated polymer is applied to the single-component organic solar battery, and no donors and no receptors are needed; separation of a nano phase of an active layer of a battery instrument can be effectively enhanced by adjusting the length of an alkyl chain on the side chain, and the instrument efficiency is improved.